Molecular and biological heterogeneity in neuroblastoma

Current Genomics

Volumn 6, Issue 5, 2005, Pages 319-332

  Hiyama, Eiso ^a   Hiyama, Keiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Chromosome; MYCN; Neuroblastoma; Ploidy; Prognosis; Telomerase; Telomere

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; NEUROTROPHIN RECEPTOR; PROTEIN C MYB; PROTEIN P53; PROTEIN TYROSINE KINASE; TELOMERASE; TUMOR SUPPRESSOR PROTEIN; TYROSINE KINASE RECEPTOR;

ADRENAL MEDULLA; ADRENERGIC SYSTEM; APOPTOSIS; CANCER CELL; CANCER REGRESSION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CHILDHOOD CANCER; CHROMOSOME 1; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; DISEASE COURSE; ENZYME ACTIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GANGLIONEUROMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC MARKER; HUMAN; MOLECULAR MECHANICS; NERVE CELL NETWORK; NEURAL CREST; NEUROBLAST; NEUROBLASTOMA; OUTCOMES RESEARCH; PATIENT CARE; PLOIDY; POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; TELOMERE; TUMOR DIFFERENTIATION;

EID: 24144488241     PISSN: 13892029     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389202054750202     Document Type: Review

References (140)

1. Gurney, J. G., Ross, J. A., Wall, D. A., Bleyer, W. A., Severson, R. K. and Robison, L. L. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1. J. Pediatr. Hematol. Oncol., 1997, 19, 428-32.
2. Evans, A. E., Gerson, J. and Schnaufer, L. Spontaneous regression of neuroblastoma. Natl. Cancer Inst. Monogr., 1976, 44, 49-54.
3. Evans, A. E., Baum, E. and Chard, R. Do infants with stage IV-S neuroblastoma need treatment? Arch. Dis. Child, 1981, 56, 271-4.
4. Haas, D., Ablin, A. R., Miller, C., Zoger, S. and Matthay, K. K. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer, 1988, 62, 818-25.
5. Fiorillo, A., Migliorati, R., Tamburrini, O., Pellegrini, F., Vecchio, P., Buffolano, W. and De Bernardi, B. Prolonged survival of a patient with disseminated neuroblastoma. J. Pediatr., 1982, 101, 564-6.
6. Bessho, F., Hashizume, K., Nakajo, T. and Kamoshita, S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J. Pediatr., 1991, 119, 237-41.
7. Berthold, F., Baillot, A., Hero, B., Schurr, P., Nerenz, A., Hunneman, D. H. and Sander, J. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany. J. Clin. Oncol., 1999, 17, 1200.
8. Woods, W. G., Lemieux, B. and Tuchman, M. Neuroblastoma represent distinct clinical-biologic entities: a review and perspective from Quebec neuroblastoma screening project. Pediatrics, 1992, 88, 114-8.
9. Brodeur, G. M., Maris, J. M., Yamashiro, D. J., Hogarty, M. D. and White, P. S. Biology and genetics of human neuroblastomas. J. Pediatr. Hematol. Oncol., 1997, 19, 93-101.
10. Brodeur, G. M. Molecular basis for heterogeneity in human neuroblastoma. Eur. J. Cancer, 1995, 31A, 505-10.
11. Schwab, M. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes. Naturwissenschaften, 1999, 86, 71-8.
12. Shimada, H., Chatten, J., Newton, W. J., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B. and Misugi, K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst., 1984, 73, 405-16.
13. Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer, 1999, 86, 364-72.
14. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. and Bishop, J. M. Amplification of N-myc in untreated human neuroblastoma correlated with advanced stage. Science, 1984, 224, 1121-4.
15. Schwab, M., Varmus, H. E., Bishop, J. M., Grzeschik, K. H., Naylor, S. L., Sakaguchi, A. Y., Brodeur, G. and Trent, J. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature, 1984, 308, 288-91.
16. Perez, C. A., Matthay, K. K., Atkinson, J. B., Seeger, R. C., Shimada, H., Haase, G. M., Stram, D. O., Gerbing, R. B. and Lukens, J. N. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J. Clin. Oncol., 2000, 18, 18-26.
17. Berthold, F., Hero, B., Kremens, B., Handgretinger, R., Henze, G., Schilling, F. H., Schrappe, M., Simon, T. and Spix, C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997, with stage 4 neuroblastoma over 1 year of age. Cancer Lett., 2003, 197, 11-7.
18. Kaneko, M., Nishihira, H., Mugishima, H., Ohnuma, N., Nakada, K., Kawa, K., Fukuzawa, M., Suita, S., Sera, Y. and Tsuchida, Y. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Med. Pediatr. Oncol., 1998, 31, 1-7.
19. Kaneko, M., Tsuchida, Y., Mugishima, H., Ohnuma, N., Yamamoto, K., Kawa, K., Iwafuchi, M., Sawada, T. and Suita, S. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J. Pediatr. Hematol. Oncol., 2002, 24, 613-21.
20. Squire, J. A., Thorner, P., Marrano, P., Parkinson, D., Ng, Y. K., Gerrie, B., Chilton-Macneill, S. and Zielenska, M. Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations. Mol. Diagn., 1996, 1, 281-9.
21. Spitz, R., Hero, B., Skowron, M., Ernestus, K. and Berthold, F. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Eur. J. Cancer, 2004, 40, 2753-9.
22. Shapiro, D. N., Valentine, M, B., Rowe, S. T., Sinclair, A. E., Sub-Lett., J. E., Roberts, W. M. and Look, A. T. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am. J. Pathol., 1993, 142, 1339-46.
23. Brodeur, G. M., Hayes, F. A., Green, A. A., Casper, J. T., Wasson, J., Wallach, S. and Seeger, R. C. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res., 1987, 47, 4248-53.
24. Ohtsu, K., Hiyama, E., Ichikawa, T., Matsuura, Y. and Yokoyama, T. Clinical Investigation of Neuroblastoma with Partial Deletion in the Short Arm of Chromosome Clinical. Cancer Res., 1997, 3, 1221-8.
25. Hiyama, E., Hiyama, K. and Yokoyama, T. Neuroblastoma with DNA amplification and rearrangement in the N-myc gene region. Cancer Res., 1991, 51, 1946-51.
26. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 1999, 340, 1954-61.
27. Amler, L. C. and Schwab, M. Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. Mol. Cell. Biol., 1989, 9, 4903-13.
28. Cohn, S. L., London, W. B., Huang, D., Katzenstein, H. M., Salwen, H. R., Reinhart, T., Madafiglio, J., Marshall, G. M., Norris, M. D. and Haber, M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J. Clin. Oncol., 2000, 18, 3604-13.
29. Hiyama, E., Hiyama, K., Yokoyama, T. and Ishii, T. Immunohistochemical analsysis of N-myc protein expression in neuroblastoma: Correlation with prognosis of patients. J. Pediatr. Surg., 1991, 26, 838-43.
30. Bordow, S. B., Norris, M. D., Haber, P. S., Marshall, G. M. and Haber, M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol., 1998, 16, 3286-94.
31. Gansler, T., Chatten, J., Varello, M., Bunin, G. R. and Atkinson, B. Flow cytometric DNA analysis of neuroblastoma: correlation with histology and clinical outcome. Cancer, 1986, 58, 2453-8.
32. Look, A. T., Hayes, F. A., Shuster, J. J., Douglass, E. C., Castleberry, R. P., Bowman, L. C., Smith, E. I. and Brodeur, G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol., 1991, 9, 581-91.
33. Kaneko, Y., Kanda, N., Maseki, N., Sakurai, M., Tsuchida, Y., Takeda, T. and Okabe, I. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res., 1987, 47, 311-8.
34. Ladenstein, R., Ambros, I. M., Potschger, U., Amann, G., Urban, C., Fink, F. M., Schmitt, K., Jones, R., Slociak, M., Schilling, F., et al. Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med. Pediatr. Oncol., 2001, 36, 83-92.
35. Plantaz, D., Vandesompele, J., Van Roy, N., Lastowska, M., Bown, N., Combaret, V., Favrot, M. C., Delattre, O., Michon, J., Benard, J., et al. Comparative genomic hybridization (CGH, analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int. J. Cancer, 2001, 91, 680-6.
36. Lastowska, M., Nacheva, E., McGuckin, A., Curtis, A., Grace, C., Pearson, A. and Bown, N. Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromo. Cancer, 1997, 18, 162-9.
37. Vandesompele, J., Van Roy, N., Van Gele, M., Laureys, G., Ambros, P., Heimann, P., Devalck, C., Schuuring, E., Brock, P., Otten, J., et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromo. Cancer, 1998, 23, 141-52.
38. Fong, C. T., Dracopoli, N. C., White, P. S., Merrill, P. T., Griffith, R. C., Houseman, D. E. and Brodeur, G. M. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblasotma: corrlation with N-myc amplification. Proc. Natl. Acad. Sci. USA, 1989, 86, 3753-7.
39. Kohno, T., Morishita, K., Takano, H., Shapiro, D. N. and Yokota, J. Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting. Oncogene, 1994, 9, 103-8.
40. Gilbert, F., Balaban, G., Moorhead, P., Bianchi, D. and Schlesinger, H. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet. Cytogenet., 1982, 7, 33-42.
41. Takeda, O., Homma, C., Maseki, N., Sakurai, M., Kanda, N., Schwab, M., Nakamura, Y. and Kaneko, Y. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes. Chromo. Cancer, 1994, 10, 30-9.
42. Hiyama, E., Hiyama, K., Ohtsu, K., Yamaoka, H., Fukuba, I., Matsuura, Y. and Yokoyama, T. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome Med. Pediatr. Oncol., 2001, 36, 67-74.
43. Caron, H., Peter, M., van Sluis, P., Speleman, F., de Kraker, J., Laureys, G., Michon, J., BrugieRes., L., Voute, P. A., Westerveld, A., et al. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. Hum. Mol. Genet, 1995, 4, 535-9.
44. Spieker, N., Beitsma, M., Van Sluis, P., Chan, A., Caron, H. and Versteeg, R. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.Genes Chromo. Cancer, 2001, 31, 172-81.
45. Caron, H., van Sluis, P., van Hoeve, M., de Kraker, J., Bras, J., Slater, R., Mannens, M., Voute, P. A., Westerveld, A. and Versteeg, R. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat. Genet., 1993, 4, 187-90.
46. Cheng, J. M., Hiemstra, J. L., Schneider, S. S., Naumova, A., Cheung, N. K., Cohn, S. L., Diller, L., Sapienza, C. and Brodeur, G. M. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat. Genet., 1993, 4, 191-4.
47. Martinsson, T., Sjoberg, R. M., Hedborg, F. and Kogner, P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res., 1995, 55, 5681-6.
48. Hogarty, M. D., Maris, J. M., White, P. S., Guo, C. and Brodeur, G. M. Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Med. Pediatr. Oncol., 2001, 36, 52-5.
49. Maris, J. M., Weiss, M. J., Guo, C., Gerbing, R. B., Stram, D. O., White, P. S., Hogarty, M. D., Sulman, E. P., Thompson, P. M., Lukens, J. N., et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J. Clin. Oncol., 2000, 18, 1888-99.
50. Gilbert, F., Feder, M., Balaban, G., Brangman, D., Lurie, D.K., Podolsky, R., Rinalds, V., Vinikoor, N. and Weisband, J. Human neuroblastoma and abnormalities of chromosomes 1 and 17. Cancer Res., 1984, 44, 5444-9.
51. Schweigerer, L., Breit, S., Wenzel, A., Tsunamoto, K., Ludwig, R. and Schwab, M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res., 1990, 50, 4411-6.
52. Lutz, W., Fulda, S., Jeremias, I., Debatin, K. M. and Schwab, M. MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene, 1998, 17, 339-46.
53. Savelyeva, L., Corvi, R. and Schwab, M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am. J. Hum. Genet., 1994, 55, 334-40.
54. Van Roy, N., Laureys, G., Cheng, N. C., Willem, P., Opdenakker, G., Versteeg, R. and Speleman, F. 1;17 translocations and other chromosome 17 rearrangements in human primary neuroblastoma tumors and cell lines. Genes Chromo. Cancer, 1994, 10, 103-14.
55. Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M. and Altieri, D. C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet, 1998, 351, 882-3.
56. Godfried, M. B., Veenstra, M., v Sluis, P., Boon, K., v Asperen, R., Hermus, M. C., v Schaik, B. D., Voute, T. P., Schwab, M., Versteeg, R., et al. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H. Oncogene, 2002, 21, 2097-101.
57. Leone, A., Seeger, R. C., Hong, C. M., Hu, Y. Y., Arboleda, M. J., Brodeur, G. M., Stram, D., Slamon, D. J. and Steeg, P. S. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene, 1993, 8, 855-65.
58. Mertens, F., Johansson, B., Hoglund, M. and Mitelman, F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res., 1997, 57, 2765-80.
59. Koiffmann, C. P., Gonzalez, C. H., Vianna-Morgante, A. M., Kim, C. A., Odone-Filho, V. and Wajntal, A. Neuroblastoma in a boy with MCA/MR syndrome, deletion 11q, and duplication 12q. Am. J. Med. Genet., 1995, 58, 46-9.
60. Bown, N. P., Pearson, A. D. and Reid, M. M. High incidence of constitutional balanced translocations in neuroblastoma. Cancer Genet. CytoGenet., 1993, 69, 166-7.
61. Hecht, F., Hecht, B. K., Northrup, J. C., Trachtenberg, N., Wood, T. S. and Cohen, J. D. Genetics of familial neuroblastoma: long-range studies. Cancer Genet. CytoGenet., 1982, 7, 227-30.
62. Takita, J., Hayashi, Y., Kohno, T., Shiseki, M., Yamaguchi, N., Hanada, R., Yamamoto, K. and Yokota, J. Allelotype of neuroblastoma. Oncogene, 1995, 11, 1829-34.
63. Fong, C. T., White, P. S., Peterson, K., Sapienza, C., Cavenee, W. K., Kern, S. E., Vogelstein, B., Cantor, A. B., Look, A. T. and Brodeur, G. M. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res., 1992, 52, 1780-5.
64. Takeda, O., Handa, M., Uehara, T., Maseki, N., Sakashita, A., Sakurai, M., Kanda, N., Arai, Y. and Kaneko, Y. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas. Br. J. Cancer, 1996, 74, 1620-6.
65. Guo, C., White, P. S., Hogarty, M. D., Brodeur, G. M., Gerbing, R., Stram, D. O. and Maris, J. M. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med. Pediatr. Oncol., 2000, 35, 544-6.
66. Guo, C., White, P. S., Weiss, M. J., Hogarty, M. D., Thompson, P. M., Stram, D. O., Gerbing, R., Matthay, K. K., Seeger, R. C., Brodeur, G. M., et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-57.
67. Maris, J. M., Guo, C., White, P. S., Hogarty, M. D., Thompson, P. M., Stram, D. O., Gerbing, R., Matthay, K. K., Seeger, R. C. and Brodeur, G. M. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med. Pediatr. Oncol., 2001, 36, 24-7.
68. McArdle, L., McDermott, M., Purcell, R., Grehan, D., O'Meara, A., Breatnach, F., Catchpoole, D., Culhane, A. C., Jeffery, I., Gallagher, W. M., et al. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis, 2004, 25, 1599-609.
69. Maris, J. M., Weiss, M. J., Mosse, Y., Hii, G., Guo, C., White, P. S., Hogarty, M. D., Mirensky, T., Brodeur, G. M., Rebbeck, T. R., et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-Cancer Res., 2002, 62, 6651-8.
70. Furuta, S., Ohira, M., Machida, T., Hamano, S. and Nakagawara, A. Analysis of loss of heterozygosity at 16p12-p13 (familial neuroblastoma locus, in 470 neuroblastomas including both sporadic and mass screening tumors. Med. Pediatr. Oncol., 2000, 35, 531-3.
71. Weiss, W. A., Godfrey, T., Francisco, C. and Bishop, J. M. Genome-wide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res., 2000, 60, 2483-7.
72. Tonini, G. P., Lo, C. C., Cusano, R., Iolascon, A., Dagnino, M., Conte, M., Milanaccio, C., De, B. B., Mazzocco, K. and Scaruffi, P. Loss of heterozygosity for chromosome 1p in familial neuroblastoma. Eur. J. Cancer, 1997, 33, 1953-6.
73. Hallstensson, K., Thulin, S., Aburatani, H., Hippo, Y. and Martinsson, T. Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma. Eur. J. Cancer, 1997, 33, 1966-70.
74. Ejeskar, K., Aburatani, H., Abrahamsson, J., Kogner, P. and Martinsson, T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br. J. Cancer, 1998, 77, 1787-91.
75. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S. and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.2000, Nat. Genet., 25, 315-9.
76. Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P., Voutilainen, R., Dahia, P., et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene, 2001, 20, 7573-7.
77. Tanaka, T., Sugimoto, T. and Sawada, T. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening. Cancer, 1998, 83, 1626-33.
78. Lastowska, M., Cotterill, S., Pearson, A. D., Roberts, P., McGuckin, A., Lewis, I. and Bown, N. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur. J. Cancer, 1997, 33, 1627-33.
79. Brinkschmidt, C., Poremba, C., Christiansen, H., Simon, R., Schafer, K. L., Terpe, H. J., Lampert, F., Boecker, W. and Dockhorn-Dworniczak, B. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4S neuroblastomas. Br. J. Cancer, 1998, 77, 2223-9.
80. Hackett, C. S., Hodgson, J. G., Law, M. E., Fridlyand, J., Osoegawa, K., de Jong, P. J., Nowak, N. J., Pinkel, D., Albertson, D. G., Jain, A., et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res., 2003, 63, 5266-73.
81. Knudson A. G., Jr. and Strong, L. C. Mutation and cancer: neuroblastoma and pheochromocytoma. Am. J. Hum. Genet., 1972, 24, 514-32.
82. Vogan, K., Bernstein, M., Leclerc, J. M., Brisson, L., Brossard, J., Brodeur, G. M., Pelletier, J. and Gros, P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res., 1993, 53, 5269-73.
83. Moll, U. M., LaQuaglia, M., Benard, J. and Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA, 1995, 92, 4407-11.
84. Tweddle, D. A., Malcolm, A. J., Bown, N., Pearson, A. D. and Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res., 2001, 61, 8-13.
85. Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J. and Reynolds, C. P. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med. Pediatr. Oncol., 2000, 35, 563-8.
86. Beltinger, C. P., White, P. S., Sulman, E. P., Maris, J. M. and Brodeur, G. M. No CDKN2 mutations in neuroblastomas. Cancer Res., 1995, 55, 2053-5.
87. Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M. and Kidd, V. J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med., 2000, 6, 529-35.
88. Eggert, A., Grotzer, M. A., Zuzak, T. J., Wiewrodt, B. R., Ho, R., Ikegaki, N. and Brodeur, G. M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res., 2001, 61, 1314-9.
89. Harada, K., Toyooka, S., Shivapurkar, N., Maitra, A., Reddy, J. L., Matta, H., Miyajima, K., Timmons, C. F., Tomlinson, G. E., Mastrangelo, D., et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res., 2002, 62, 5897-901.
90. Takita, J., Yang, H. W., Chen, Y. Y., Hanada, R., Yamamoto, K., Teitz, T., Kidd, V. and Hayashi, Y. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene, 2001, 20, 4424-32.
91. Fulda, S., Lutz, W., Schwab, M. and Debatin, K. M. MycN sensitizes neuroblastoma cells for drug-triggered apoptosis. Med. Pediatr. Oncol., 2000, 35, 582-4.
92. van Noesel, M. M., van Bezouw, S., Salomons, G. S., Voute, P. A., Pieters, R., Baylin, S. B., Herman, J. G. and Versteeg, R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res., 2002, 62, 2157-61.
93. van Noesel, M. M., van Bezouw, S., Voute, P. A., Herman, J. G., Pieters, R. and Versteeg, R. Clustering of hypermethylated genes in neuroblastoma. Genes Chromo. Cancer, 2003, 38, 226-33.
94. Nakagawara, A., Arima, M., Azar, C. G., Scavarda, N. J. and Brodeur, G. M. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res., 1992, 52, 1364-8.
95. Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B. and Brodeur, G. M. Association between high levels of expression of the trk gene and favorable outcome in human neuroblastoma. N. Engl. J. Med., 1993, 328, 847-54.
96. Suzuki, T., Bogenmann, E., Shimada, H., Stram, D. and Seeger, R. C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J. Natl. Cancer Inst., 1993, 85, 377-84.
97. Kogner, P., Barbary, G., Dominici, C., Castello, M. A., Raschella, G. and Persson, H. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res., 1993, 53, 2044-50.
98. Nakagawara, A. The NGF story and neuroblastoma. Med. Pediatr. Oncol., 1998, 31, 113-5.
99. Nakagawara, A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum. Cell, 1998, 11, 115-24.
100. Nakagawara, A., Azar, C. G., Scavarda, N. J. and Brodeur, G. M. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol. Cell. Biol., 1994, 14, 759-67.
101. Matsumoto, K., Wada, R. K., Yamashiro, J. M., Kaplan, D. R. and Thiele, C. J. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res., 1995, 55, 1798-806.
102. Yamashiro, D. J., Nakagawara, A., Ikegaki, N., Liu, X. G. and Brodeur, G. M. Expression of TrkC in favorable human neuroblastomas. Oncogene, 1996, 12, 37-41.
103. Zakian, V. A. Structure and function of telomeres. Annu. Rev. Genet., 1989, 23, 579-604.
104. Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. The RNA component of human telomerase. Science, 1995, 269, 1236-41.
105. Harley, C. B., Kim, N. W., Prowse, K. L., Weinrich, S. L., Hirsh, K. S., West, M. D., Bacchetti, S., Hirte, H. W., Counter, C. M., Greider, C. W., et al. Telomerase, cell immortality, and Cancer Cold Spring Harbor Symposia on Quantitative. Biology, 1994, 59, 307-15.
106. Shay, J. W. and Bacchetti, S. A survey of telomerase activity in human Cancer Eur. J. Cancer, 1997, 33, 787-91.
107. Shay, J. W., Werbin, H. and Wright, W. E. Telomerase assay in the diagnosis and prognosis of Cancer. Ciba. Found. Symp., 1997, 211, 148-55.
108. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L. and Shay, J. W. Specific association of human telomerase activity with immortal cells and Cancer. Science, 1994, 266, 2011-5.
109. Piatyszek, M. A., Kim, N. W., Weinrich, S. L., Hiyama, K., Hiyama, E., Wright, W. E. and Shay, J. W. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Meth. Cell. Science, 1995, 17, 1-15.
110. Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A. and Shay, J. W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med., 1995, 1, 249-55.
111. Hiyama, E., Hiyama, K., Ohtsu, K., Yamaoka, H., Ichikawa, T., Shay, J. W. and Yokoyama, T. Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behavior? Eur. J. Cancer, 1997, 33, 1932-6.
112. Reynolds, C. P., Zuo, J. J., Kim, N. W., Wang, H., Lukens, J. N., Matthay, K. K. and Seeger, R. C. Telomerase expression in primary neuroblastomas. Eur. J. Cancer, 1997, 33, 1929-31.
113. Poremba, C., Willenbring, H., Hero, B., Christiansen, H., Schafer, K. L., Brinkschmidt, C., Jurgens, H., Bocker, W. and Dockhorn-Dworniczak, B. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann. Oncol., 1999, 10, 715-21.
114. Hiyama, E., Hiyama, K., Yokoyama, T., Ichikawa, T. and Matsuura, Y. Length of telomeric repeats in neuroblastoma: Correlation with prognosis and other biological characteristics. Jpn. J. Cancer Res., 1992, 83, 159-64.
115. Hiyama, E., Yokoyama, T., Hiyama, K., Michio, Y., Santo, T., Kodama, T., Ichikawa, T. and Matsuura, Y. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int. J. Oncol., 1995, 6, 13-6.
116. Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W. and Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet., 1996, 18, 173-9.
117. Turkel, S. B. and Itabashi, H. H. The natural history of neuroblastic cells in the fetal adrenal gland. Am. J. Pathol., 1974, 76, 225-44.
118. Ikeda, Y., Lister, J., Bouton, J. M. and Buyukpamukcu, M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J. Pediatr. Surg., 1981, 16, 636-44.
119. Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B. and Cech, T. R. Telomerase catalytic subunit homologs from fission yeast and human. Science, 1997, 277, 955-9.
120. Koyanagi, Y., Kobayashi, D., Yajima, T., Asanuma, K., Kimura, T., Sato, T., Kida, T., Yagihashi, A., Kameshima, H. and Watanabe, N. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. AntiCancer Res., 2000, 20, 773-8.
121. Krams, M., Hero, B., Berthold, F., Parwaresch, R., Harms, D. and Rudolph, P. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am. J. Pathol., 2003, 162, 1019-26.
122. Poremba, C., Hero, B., Heine, B., Scheel, C., Schaefer, K. L., Christiansen, H., Berthold, F, Kneif, S., Stein, H., Juergens, H., Boecker, W. and Dockhorn-Dworniczak, B. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med. Pediatr. Oncol., 2000, 35, 651-5.
123. Hiyama, E. and Hiyama, K. Clinical utility of telomerase in Cancer Oncogene, 2002, 21, 643-9.
124. Ulaner, G. A., Hu, J. F., Vu, T. H., Giudice, L. C. and Hoffman, A. R. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT, transcription and by alternate splicing of hTERT transcripts. Cancer Res., 1998, 58, 4168-72.
125. Hiyama, E., Hiyama, K., Shay, J. W. and Yokoyama, T. Immunhistochemical detection of telomerase (hTERT, protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia, 2001, 3, 17-26.
126. Kumaki, F., Kawai, T., Hiroi, S., Shinomiya, N., Ozeki, Y., Ferrans, V. J. and Torikata, C. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum. Pathol., 2001, 32, 188-95.
127. Kumaki, F., Takeda, K., Yu, Z. X., Moss, J. and Ferrans, V. J. Expression of human telomerase reverse transcriptase in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med., 2002, 166, 187-91.
128. Chou, S. J., Chen, C. M., Harn, H. J., Chen, C. J. and Liu, Y. C. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma. J. Surg. Res., 2001, 99, 75-83.
129. Fletcher, T. M., Salazar, M. and Chen, S. F. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry, 1996, 35, 15611-7.
130. Norton, J. C., Piatyszek, M. A., Wright, W. E., Shay, J. W. and Corey, D. R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol., 1996, 14, 615-9.
131. Kanazawa, Y., Ohkawa, K., Ueda, k., Mita, E., Takehara, T., Sasaki, Y., Kasahara, A. and Hayashi, N. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Comm., 1996, 225, 570-6.
132. Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R. and Deen, D. F. Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-Oncol., 2004, 6, 218-26.
133. Sharma, S., Raymond, E., Soda, H., Sun, D., Hilsenbeck, S. G., Sharma, A., Izbicka, E., Windle, B. and Von, H. D. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol., 1997, 8, 1063-74.
134. Reynolds, C.P., Zuo, J.J., Hong, C.M., Kim, N.W. and Seeger, R.C. Telomerase RNA expression in neuroblastoma correlates with high stage and clinical outcome. Proc. Amer. Assoc. Cancer Res., 1996, 37, 199.
135. Dockhorn-Dworniczak, B., Willenbrin, H., Poremba, C., Schafer, K.L., Brinkschmidt, C., Terpe, H.J., Christiansen, H., Bocker, W. and Jurgens, H. Telomerase activity (TA) distinguishes poor from favourable prognosis in neuroblastomas. Proc. Amer. Assoc. Cancer Res., 1998, 17, 553a.
136. Choi, M.R., Kim, N.W., Amshey, S., Zuo, J.I. Seeger, R.C. and Reynolds, C.P. Comparison of telomerase activity and telomerase RNA component expression in neuroblastoma. Proc. Amer. Assoc. Cancer Res., 1999, 40, 201.
137. Isobe, K., Yashiro, T., Omura, S., Kaneko, M., Kaneko, S., Kamma, H., Tatsuno, I., Takekoshi, K., Kawakami, Y. and nakai, T. Expression of the human telomerase reverse transcriptase in pheochromocytoma and neuroblastoma tissues. Endocr. J., 2004, 51, 47-52.
138. Streutker, C.J., Thorner, P., Fabricius, N., Weitzman, S. and Zielenska, M. Telomerase activity as a prognostic factor in neuroblastomas. Pediatr. Dev. Pathol., 2001, 4, 62-7.
139. Nozaki, C., Horibe, K., Iwata, H., Ishiguro, Y., Hamaguchi, M. and Takahashi, M. Prognostic impact of telomerase activity in patients with neuroblastoma. Int. J. Oncol., 2000, 17, 341-5.
140. Maitra, A., Yashima, K., Rathi, A., Timmons, C.F., Rogers, B.B., Shay, J.W. and Gazdar, A.F. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer, 1999, 85, 741-9.